Novo Nordisk A/S (NVO) Q3 2016 Earnings Results

Novo Nordisk Beats on EPS, Stock Down 0.89%

This earnings report shows that Novo Nordisk had a positive surprise on EPS, indicating better-than-expected profitability. However, the stock reacted negatively, which could be due to a lack of revenue data or concerns about future growth. Investors will be looking for more clarity in upcoming reports.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.57	N/A	+0.89%

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed confidence in the company's product pipeline and market position. They acknowledged challenges but remain focused on long-term growth.

Management highlighted strong demand for diabetes and obesity treatments.

They emphasized ongoing investment in research and development.

There was a focus on maintaining market leadership despite competitive pressures.

Novo Nordisk Beats on EPS, Stock Down 0.89%

Key numbers

Management commentary

Novo Nordisk A/S

More earnings this week

Novo Nordisk Beats on EPS, Stock Down 0.89%

Key numbers

Management commentary